Marquette Asset Management LLC Makes New Investment in NextCure, Inc. (NASDAQ:NXTC)

Marquette Asset Management LLC bought a new stake in NextCure, Inc. (NASDAQ:NXTC) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 58,259 shares of the company’s stock, valued at approximately $66,000. Marquette Asset Management LLC owned 0.21% of NextCure at the end of the most recent reporting period.

Separately, Acuitas Investments LLC increased its stake in NextCure by 30.0% in the 4th quarter. Acuitas Investments LLC now owns 372,799 shares of the company’s stock valued at $425,000 after buying an additional 85,982 shares during the period. Institutional investors and hedge funds own 42.65% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on NXTC. HC Wainwright upped their price target on shares of NextCure from $5.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Needham & Company LLC restated a “buy” rating and issued a $4.00 target price on shares of NextCure in a research note on Wednesday, March 20th.

NextCure Price Performance

NXTC traded up $0.06 during midday trading on Friday, hitting $1.35. 56,503 shares of the company’s stock traded hands, compared to its average volume of 156,876. The company has a market cap of $37.67 million, a PE ratio of -0.60 and a beta of 0.40. NextCure, Inc. has a one year low of $0.98 and a one year high of $2.57. The stock’s fifty day simple moving average is $1.74 and its 200-day simple moving average is $1.39.

NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.02. On average, research analysts expect that NextCure, Inc. will post -1.65 EPS for the current year.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.